Economic consequences of multiple sclerosis for Canadians.
To estimate the total costs of multiple sclerosis (MS) for all Canadians in 1994.
Prevalence-based study estimating disease-related societal costs for Canadians with MS in 1994.
The human capital approach was used to estimate the value of lost productivity due to illness.
Two components were revealed : first, direct costs, in terms of expenditures on hospital care, other institutions, physician services, other health professionals, drugs, and other expenditures ; and second, indirect costs, in terms of lost productivity due to premature mortality and disability.
The total costs of MS for Canadians were $502.3 million in 1994, with direct and indirect cost components at $188.6 million and $313.7 million, respectively.
This study highlights the scope and magnitude of the economic consequences of MS for Canadians.
The costs calculated may be used to provide guidance in the setting of national priorities for research and prevention activities.
Mots-clés Pascal : Sclérose en plaque, Analyse coût, Canada, Amérique du Nord, Amérique, Economie santé, Homme, Système nerveux pathologie, Système nerveux central pathologie, Maladie inflammatoire
Mots-clés Pascal anglais : Multiple sclerosis, Cost analysis, Canada, North America, America, Health economy, Human, Nervous system diseases, Central nervous system disease, Inflammatory disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0306118
Code Inist : 002B17F. Création : 15/07/1997.